Literature DB >> 21903823

Emergence of carbapenem-resistant clinical Enterobacteriaceae isolates from a teaching hospital in Shanghai, China.

Fupin Hu1, Shudan Chen2,1, Xiaogang Xu1, Yan Guo1, Yang Liu1, Demei Zhu1, Yingyuan Zhang1.   

Abstract

Carbapenems such as imipenem and meropenem are first-line agents for the treatment of serious nosocomial infections caused by multidrug-resistant clinical isolates of bacteria belonging to the family Enterobacteriaceae. However, resistance to carbapenems has increased dramatically among members of the family Enterobacteriaceae isolated from a teaching hospital in Shanghai, China. In the present study, we investigated the prevalence and molecular characteristics of carbapenem-resistant clinical isolates of Enterobacteriaceae. None of the 77 clinical isolates collected from 2002 to 2009 were susceptible to ertapenem and only 6.5 % and 1.3 % of isolates were susceptible to imipenem and meropenem, respectively. Colistin and tigecycline were found to be the most active agents against carbapenem-resistant Enterobacteriaceae isolates, inhibiting 90 % of isolates at a concentration of 1 µg ml(-1) and 4 µg ml(-1), respectively. The results of PFGE analysis suggested that many of the KPC-2-producing isolates of Citrobacter freundii and Klebsiella pneumoniae were clonally related. Most of these isolates were isolated from the same ward, namely the neurosurgical ward, suggesting horizontal transfer of the KPC-2-encoding gene in these isolates. Of the 77 isolates, 84.4 % were found, by PCR, to be capable of carbapenemase production. SDS-PAGE analysis revealed that 75.3 % (58/77) of the isolates had lost at least one porin protein. Our results suggested that the prompt detection of carbapenemase-producing strains is critical for the containment of nosocomial transmission. As no novel antimicrobials have been identified for use in the treatment of these pan-drug-resistant isolates, further studies should focus on the rational use of available antibiotics, the implementation of active antibiotic resistance surveillance and the strict implementation of infection control measures to avoid the rapid spread or outbreak of carbapenemase-producing Enterobacteriaceae in health-care facilities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903823     DOI: 10.1099/jmm.0.036483-0

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  24 in total

1.  Characteristics of carbapenemase-producing Klebsiella pneumoniae as a cause of neonatal infection in Shandong, China.

Authors:  Yan Jin; Xiaofei Song; Yigang Liu; Yong Wang; Bingchang Zhang; Hui Fan; Chunhong Shao
Journal:  Exp Ther Med       Date:  2017-01-20       Impact factor: 2.447

2.  Outbreak of Klebsiella pneumoniae carbapenemase-2-producing K. pneumoniae sequence type 11 in Taiwan in 2011.

Authors:  Chun-Ming Lee; Chun-Hsing Liao; Wen-Sen Lee; Yung-Ching Liu; Jung-Jung Mu; Meng-Chih Lee; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

3.  Waging war against extended spectrum Beta lactamase and metallobetalactamase producing pathogens- novel adjuvant antimicrobial agent cse1034- an extended hope.

Authors:  Manisa Sahu; S Sanjith; Pallavi Bhalekar; Dipti Keny
Journal:  J Clin Diagn Res       Date:  2014-06-20

4.  Rapid Identification of Klebsiella pneumoniae by Matrix-Assisted Laser Desorption/Ionization-Time of Flight Mass Spectrometry and Detection of Meropenem Resistance by Flow Cytometric Assay.

Authors:  Abdullah Kilic; Eyup Dogan; Sinem Kaya; Sema Oren; Duran Tok; Nurittin Ardic; Mehmet Baysallar
Journal:  J Clin Lab Anal       Date:  2016-05-30       Impact factor: 2.352

5.  Four carbapenem-resistant gram-negative species carrying distinct carbapenemases in a single patient.

Authors:  Baixing Ding; Fupin Hu; Yang Yang; Qinglan Guo; Jinwei Huang; Minggui Wang
Journal:  J Clin Microbiol       Date:  2014-12-31       Impact factor: 5.948

6.  Management of Pneumonia and Blood Stream Infections with New Antibiotic Adjuvant Entity (Ceftriaxone + Sulbactam + Disodium Edetate)- A Novel Way to Spare Carbapenems.

Authors:  Mohammad Shameem; Mohammad Amin Mir
Journal:  J Clin Diagn Res       Date:  2016-12-01

7.  Mechanism for carbapenem resistance of clinical Enterobacteriaceae isolates.

Authors:  Yafei Ye; Lijuan Xu; Yanping Han; Zhe Chen; Cailin Liu; Liang Ming
Journal:  Exp Ther Med       Date:  2017-11-10       Impact factor: 2.447

8.  The prevalence of carbapenemase genes and plasmid-mediated quinolone resistance determinants in carbapenem-resistant Enterobacteriaceae from five teaching hospitals in central China.

Authors:  L Hu; Q Zhong; Y Shang; H Wang; C Ning; Y Li; Y Hang; J Xiong; X Wang; Y Xu; Z Qin; C Parsons; L Wang; F Yu
Journal:  Epidemiol Infect       Date:  2013-11-20       Impact factor: 4.434

9.  Identification and characterization of the first Escherichia coli strain carrying NDM-1 gene in China.

Authors:  Zhiyuan Liu; Wei Li; Jie Wang; Jian Pan; Shipeng Sun; Yanhua Yu; Bing Zhao; Yuzhi Ma; Tingju Zhang; Jie Qi; Guijian Liu; Fengmin Lu
Journal:  PLoS One       Date:  2013-06-10       Impact factor: 3.240

10.  Epidemiology and clinical features of bloodstream infections in hematology wards: one year experience at the catholic blood and marrow transplantation center.

Authors:  Jae-Cheol Kwon; Si-Hyun Kim; Jae-Ki Choi; Sung-Yeon Cho; Yeon-Joon Park; Sun Hee Park; Su-Mi Choi; Dong-Gun Lee; Jung-Hyun Choi; Jin-Hong Yoo
Journal:  Infect Chemother       Date:  2013-03-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.